drugset / Trial / NCT00818571

Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

NCT00818571

Phase 1/2 Completed 96 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study assess the pharmacokinetics of vildagliptin in mild, moderate and severe renal impaired patients

Timeline

Start
2008-12
Primary completion
2009-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Vildagliptin Other / unclassified 25 mg
Subject Vildagliptin Other / unclassified 50 mg